분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-09-17 10:51:45 , Hit : 1710
 Gilead Licenses Hepatitis Therapy in India Amid Price Criticism

By Ketaki Gokhale  Sep 15, 2014 11:45 PM GMT+0900   2 Comments    Email  Print    




Nov2014MarMayJulSep60.0080.00100.00* Price chart for GILEAD SCIENCES INC. Click flags for important stories. GILD:US104.763.77 3.73%



Gilead Sciences Inc. (GILD) licensed seven India-based generic drugmakers to bring cheaper versions of Sovaldi to 91 countries, expanding the reach of a hepatitis C drug that is sold for $84,000 in the U.S.

The agreements allow Cadila Healthcare Ltd. (CDH), Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd. (MYL), Ranbaxy Laboratories Ltd. (RBXY), Sequent Scientific Ltd. (SEQ) and Strides Arcolab Ltd. (STR) to make Sovaldi, Gilead said in a statement.

The drug’s pricing has drawn criticism from pharmacy benefit managers, as well as questions from U.S. Senators Charles Grassley and Ron Wyden, who have demanded to know how Gilead came up with the figure. The agreements in India were announced amid protests from activist groups that said the licenses failed to cover key high-burden nations like China, Brazil, Mexico and Thailand.

“Our view is that the competition and the capabilities of these partners will bring down the price,” Gregg Alton, an executive vice president at Foster City, California-based Gilead, said at a news conference in New Delhi.

Gilead chose Indian partners with “the capability of large-scale manufacturing, high-quality manufacturing, and low-cost manufacturing,” Alton said. They have “the ability to supply the markets we’re talking about.”

The U.S. drugmaker plans to sell its branded version of Sovaldi in India at a cost of $900 for 12 weeks of therapy, Alton said. The drug will probably reach that market by the end of next year if clinical trials are run, and Gilead is in talks with the Indian regulator to waive the trial requirement.

Millions Infected

As many as 150 million people in the world live with chronic hepatitis C infection, according to the World Health Organization. The most common modes of infection from the blood-borne virus are unsafe injection practices, inadequate sterilization of medical equipment, and unscreened blood and blood products.

The company didn’t stipulate prices for the low-cost generic versions, Alton said. The manufacturers won’t charge more than Gilead’s “benchmark” $900 price, said Bhavesh Shah, director of international marketing at Hetero. Generic versions of Sovaldi will be available in India next year, sometime between April and September, he said.

The licenses announced today also allow the generic manufacturers to produce an experimental pill that combines Sovaldi with another Gilead hepatitis drug.

China Missing

The lower price may still be too expensive for some patients in developing regions and some key countries haven’t been included in the licensing deal, said Leena Menghaney, South Asia head of the Access Campaign at Doctors Without Borders.

The license enables the generic drugmakers to sell copies of Sovaldi in countries including Egypt, which has the world’s highest prevalence of hepatitis C, as well as India and Indonesia. Not on the list is China, which has the greatest number of people infected, at 29.8 million, according to Doctors Without Borders.

The group has criticized the agreements for not bringing coverage to middle-income countries such as Ukraine, Thailand, Mexico and Brazil. More than 70 percent of patients with hepatitis C live in middle-income countries, according to the Geneva-based organization.

“Gilead wants these profitable emerging markets for itself,” Menghaney said.

Alton said that 54 countries, or more than half of the 91 countries covered by the licenses, are middle-income markets.

Half the World

“The licenses cover about 100 million people living with hepatitis C globally, representing about 54 percent of the total global infected population,” he said. “About half of the world’s population is covered.”

Activists from Indian Drug Users Forum and Delhi Network of Positive People demonstrated outside the news conference, with signs reading “Gilead/Killead” and “Wanted: Crimes Against Access.”

Gilead’s application for a patent for Sovaldi in India is being challenged by Hyderabad-based Natco Pharma Ltd. on the grounds that the therapy “lacks novelty” and isn’t an “inventive step,” according to a filing with the patent office.

The Initiative for Medicines, Access & Knowledge, a group of scientists and lawyers, has opposed the patent on similar grounds, saying that Sovaldi is based on “old science, existing compound,” according to a statement last year.

To contact the reporter on this story: Ketaki Gokhale in Mumbai at kgokhale@bloomberg.net

To contact the editors responsible for this story: Anjali Cordeiro at acordeiro2@bloomberg.net David Risser, Kim McLaughlin







1047   Gene therapy using HIV helps children with fatal diseases, study says  이성욱 2013/07/16 2018
1046   Gene therapy 'could be used to treat blindness'Pallab Ghosh  이성욱 2014/01/23 1748
1045   Gene therapy 'hope' on impotence  이성욱 2007/06/04 5005
1044   Gene-therapy hope for β-thalassaemia patients  이성욱 2010/09/21 2483
1043   Genetic circuit kills cancer cells using unique microRNAs  이성욱 2011/09/08 4931
1042   Genetic variant linked to development of liver cancer in hepatitis C virus carriers  이성욱 2011/12/03 2622
1041   Genetically Altered Stem Cells Generate Engineered Cartilage  이성욱 2014/02/22 2057
1040   Genetically Engineered Pigs May Fly as Cancer Models  이성욱 2016/05/17 936
1039   Genetically Modified Stem Cells May Have Therapeutic Application to X-SCID  이성욱 2007/06/04 4479
1038   Genetically 'edited' fruit could soon hit supermarket shelves  이성욱 2014/08/15 1331
1037   Genomics: The single life  이성욱 2012/11/06 2088
1036   Genzyme, Voyager Launch Up-to-$845M Gene Therapy Collaboration  이성욱 2015/02/14 1277
1035   Giant viruses open Pandora's box  이성욱 2013/07/26 2026
1034   Giants of Circadian Biology Win Nobel Prize  이성욱 2017/10/03 519
1033   Gilead Drug Combination Cures Hepatitis C in HIV Patients  이성욱 2014/07/22 1654
1032   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1075
  Gilead Licenses Hepatitis Therapy in India Amid Price Criticism  이성욱 2014/09/17 1710
1030   Gilead secures approval in Japan for Sovaldi to treat genotype 2 chronic HCV  이성욱 2015/03/31 988
1029   Gilead seeks FDA OK for game-changing hepatitis C drug  이성욱 2013/04/10 2115
1028   Gilead submits fixed-dose combination ledipasvir/sofosbuvir HCV tablet for FDA approval  이성욱 2014/02/12 2345

[이전 10개] [1]..[11] 12 [13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2022 Zeroboard / skin by ROBIN